Immunovia publ AB Asset Resilience Ratio
Immunovia publ AB asset resilience ratio. Immunovia publ AB (IMMNOV) has an Asset Resilience Ratio of 83.99% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Immunovia publ AB to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immunovia publ AB (2016–2022)
Asset resilience ratio of Immunovia publ AB from 2016 to 2022. This chart shows how Immunovia publ AB's Asset Resilience Ratio has changed over time. Read IMMNOV liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immunovia publ AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Immunovia publ AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr29.27 Million | 83.99% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr29.27 Million | 83.99% |
Asset Resilience Insights
- Very High Liquidity: Immunovia publ AB maintains exceptional liquid asset reserves at 83.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Immunovia publ AB Industry Peers by Asset Resilience Ratio
Compare Immunovia publ AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Lonza Group AG
SW:LONN |
Diagnostics & Research | 3.04% |
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
Immunovia publ AB Asset Resilience Ratio by Year (2016–2022)
Immunovia publ AB asset resilience ratio by year from 2016 to 2022. The table below shows the annual Asset Resilience Ratio data for Immunovia publ AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 35.28% | Skr106.04 Million ≈ $11.41 Million |
Skr300.59 Million ≈ $32.35 Million |
-41.46pp |
| 2017-12-31 | 76.73% | Skr192.43 Million ≈ $20.71 Million |
Skr250.77 Million ≈ $26.99 Million |
-14.69pp |
| 2016-12-31 | 91.42% | Skr259.09 Million ≈ $27.88 Million |
Skr283.41 Million ≈ $30.50 Million |
-- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.